Reply  by Arko, Frank R
LETTERS TO THE EDITOR
Regarding “Is there an increased risk for DVT with
the VNUS closure procedure?”
The authors of a recent letter (Komenaka IK, Nguyen ET, J
Vasc Surg 2002;36:1311) reported two observations of deep
venous thrombosis (DVT), which occurred 1 and 6 weeks, respec-
tively, after ipsilateral limb treatment with the VNUS Closure
system (VNUS Medical Technologies) radiofrequency catheter to
obliterate reflux in the greater saphenous vein. We previously
reported the results of the first 286 limbs treated with the VNUS
Closure system without high ligation, and found an incidence of
DVT of 1.0%.1 Incidence of DVT after traditional stripping and
ligation ranges from 0.15% to 1.8%.2,3 At the Reno Vein Clinic,
more than 325 limbs have been successfully treated with the
VNUS Closure system, and DVT developed in only 1 limb, ie, a
partially occlusive common femoral vein thrombus, successfully
treated with operative thrombectomy. Experience at the Straub
Clinic in Honolulu reveals 3 instances of common femoral vein
partial thrombosis in 400 limbs treated with the VNUS Closure
system. These thromboses were identified on 24-hour postopera-
tive duplex ultrasound (US) scans, and were managed with oper-
ative thrombectomy. Experience at the Vein Institute of New
Jersey reveals thrombus extension into the common femoral vein
in only 1 of 425 limbs operated on. This thrombus was treated with
low molecular weight heparin, administered on an outpatient
basis, resulting in complete clearing of the common femoral vein.
Combining this experience at three centers yields a thrombus
extension rate of 5 per 1150 treated limbs (0.4%) and no DVT
involving other deep veins. In all five instances, DVT was asymp-
tomatic and found within 72 hours of initial treatment only at
planned surveillance duplex US scanning, which is part of the
VNUS Closure protocol.
We ask Drs. Komenaka and Nguyen if duplex US scanning was
performed after treatment in their two patients? Also, we are
curious about their choice of an open groin incision versus the
more typical distal percutaneous approach, and we wonder if this
could contribute to thrombotic potential?
The authors are commended for raising an important query
about the problem of lower extremity DVT after treatment of
varicose veins. DVT is a recognized risk with most any surgical
procedure, and VNUS Closure is no exception to this phenome-
non. Their questions would be answered by a well-designed pro-
spective study of radiofrequency catheters and vein stripping.
Judging from our experience with more than 1150 procedures,
however, the 0.4% rate of DVT after VNUS Closure of the greater
saphenous vein appears similar to that with conventional vein
stripping.
Robert F. Merchant Jr, MD
The Reno Vein Clinic
Reno, Nev
Robert L. Kistner, MD
Straub Clinic and Hospital
Honolulu, Hawaii
Lowell S. Kabnick, MD
The Vein Institute of New Jersey
Morristown, NJ
Competition of interest: Each author is a paid consultant for
VNUS Medical Technologies; R.L.K. owns stock in the
company; and R.F.M. is in their speakers bureau.
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Regarding “Intrasac flow velocities predict sealing of
type II endoleaks after endovascular abdominal aortic
aneurysm repair”
I read with interest the article by Arko et al (J Vasc Surg
2003;37:8-15) concerning spectral Doppler flow velocities used to
predict type II endoleak seal.
I agree that the flow velocities should be measured using an
angle of less than 60 degrees. The problem here is how to align the
cursor angle on the image parallel to the direction of blood flow.
Adjacent to aneurysm wall, the jet retains the cross-sectional shape
of the orifice and is probably the best place to make the measure-
ment. However, in this case the cursor angle should align with the
direction of jet flow, not the angle between the aortic aneurysm sac
and the branch vessel, which appears to be the technique used by
the authors. For example, in their Figure 2, it appears that the angle
adjustment is incorrect, or simply there is no angle adjustment. In
these circumstances the measurements are difficult to reproduce
and possibly are the reason for the wide range of flow velocities
found in each group.
Like Parent et al,1 I believe that other flow spectrum parame-
ters such as resistive index are better predictors of future seal of type
II endoleak. Specifically, endoleaks with a higher resistive index are
usually associated with a smaller sac, and in these cases the possi-
bility of spontaneous seal should be higher. Another indication of
the significance of the flow through an orifice is the length of the
jet.
Has the Stanford group looked at resistive index and length of
the jet as predictors of endoleak seal, and could they comment on
the specific technique that they use for angle correction of velocity
measurements?
Jose Maria Escribano, MD
Angiology, Vascular and Endovascular Surgery Department
University Hospital Vall d’Hebron
Barcelona, Spain
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I would like to thank Dr Escribano for his insightful comments
and questions regarding our recent manuscript. The purpose of
our study was twofold, first, to determine whether intrasac spectral
Doppler velocities can predict whether or not a type II endoleak
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will spontaneously seal, and secondly, to see if these intrasac flow
velocities corresponded to the preoperative branch vessel anatomy
seen on the CT angiogram. The results indicated that patients with
occluded or small inferior mesenteric arteries and fewer visualized
lumbar arteries had lower intrasac flow velocities (100 cm/sec)
and these endoleaks resolved within 6 months.1 Thus, the study
used both anatomic data from the CT and physiologic data from
the Duplex US to characterize these endoleaks.
In reference to angle correction: a 60 degree angle to flow
was used with color Doppler serving as a guide to determine the
flow channel—the aortic wall was not used as a guide for this
measurement. Assessment of flow velocities and direction was
performed in the aneurysm sac near the aneurysm wall. Where
there is no angle to flow, as when sampling at or near the lumbar
orifice, no angle correction is needed as flow is perpendicular to the
Doppler beam in this situation.
We did not measure resistive index (RI) in this study. It is
unclear to us how an appropriate RI measurement could be ob-
tained from a “to and fro” signal often associated with type II
endoleaks. We look forward to further research efforts by the
endovascular community to validate and apply these to the clinical
management of the patient with type II endoleaks.
Frank R. Arko, MD
Director, Endovascular Surgery
Assistant Professor of Surgery
Division of Vascular Surgery
Stanford University
Stanford, Calif
REFERENCE
1. Arko FR, Filis KA, Siedel SA, Johnson BL, Drake AR, Fogarty TJ, et al.
Intrasac flow velocities predict sealing of type II endoleaks after endovas-
cular abdominal aortic aneurysm repair. J Vasc Surg 2003;37:8-15.
doi:10.1016/S0741-5214(03)00724-9
Regarding “Veterans Affairs (VA) Cooperative Study
#362”
The Veterans Affairs (VA) Cooperative Study #362, reported
by Willard C. Johnson and colleagues (J Vasc Surg 2002;35:413-
21), did not demonstrate any difference in patency rate for warfarin
sodium (target range, 1.4-2.8 international normalized ratio
[INR]) plus aspirin (WASA) versus aspirin (ASA) in 458 patients
after peripheral venous bypass grafting. In 373 patients with
above-knee prosthetic bypass grafts, patency was significantly bet-
ter in the WASA group (risk ratio, 0.62). These results conflict with
our findings in the Dutch Bypass Oral Anticoagulants or Aspirin
(BOA) Study,1 favoring oral anticoagulant treatment after venous
bypass grafting and ASA in patients with prosthetic grafts. There-
fore we would like to highlight the two most important differences
in the design of the two trials and to discuss some differences in
results and the implications for daily practice.
First, the degree of anticoagulation was much higher in the
Dutch BOA study: target range, 3.0 to 4.5 INR. To achieve
optimal anticoagulation the target should be within this higher
range.2 The dosage of warfarin in the VA study was monitored
once a month, compared with twice a month, on average, in the
BOA study, which may have resulted in a higher proportion of time
when degree of coagulation was within the target range. There was
also a striking difference in percentage of patients who discontin-
ued anticoagulant treatment: 40% in the VA trial versus only 14% in
the Dutch BOA study. These differences in dosage and compliance
contribute considerably to the difference in antithrombotic effi-
cacy. The difference in ASA dose (325 mg/d in VA, 80 mg/d in
BOA) probably does not explain any difference in results.3
Second, the trials differed greatly in number of patients and
duration of follow-up. The sample size in the BOA study (n 
2690) was based on expected occlusion rate after average fol-
low-up of 2 years. The large number of patient-years (4560) in the
BOA study allowed for the predefined subgroup analyses accord-
ing to type of bypass procedure and graft material.4 The VA study
comprised fewer patients (831), with 2638 patient-years of follow-
up. Sample size was based on expected 6-year patency rate. Inas-
much as most occlusions occur in the first postoperative year, the
number of patients with 1-year follow-up in the VA Study was
probably too low to demonstrate a difference between the two
treatment groups.
It was surprising that the only statistically significant difference
between the two treatment groups occurred in patients with
prosthetic above-knee bypass grafts, and favored WASA. This
difference is mainly due to a higher number of occlusions in the
ASA group in the last 3 years of the study. Given the low compli-
ance with warfarin therapy, especially over the long term, and the
small number of patients (207) in this subgroup, this effect was
probably not caused by allocated treatment but by chance or other
unknown factors.
What are the implications of the VA and BOA trials for daily
practice? The common feature of both trials is the pragmatic
design, which allows generalization of the findings to daily prac-
tice. Because of a well-organized system of Dutch Anticoagulation
Clinics, anticoagulation therapy might be more effective in The
Netherlands than in the United States. This could imply that
addition of low-dose warfarin therapy to ASA treatment in the
United States has little or no effect, whereas in the Dutch health
care setting oral anticoagulant agents are more effective than ASA
for prevention of venous graft occlusion. For patients with pros-
thetic bypass grafts, ASA remains the best antithrombotic treat-
ment, worldwide.
The authors of the VA Study have improved knowledge of
antithrombotic therapy and discussed their findings clearly. We
hope to have added further clarification with our expertise and this
contribution to the discussion.
Marco J.D. Tangelder
Ale Algra
James Lawson
Hero van Urk
Bert C. Eikelboom
on behalf of the Steering Committee of the Dutch BOA Study
University Hospital Utrecht, Vascular Surgery/BOA Trial Office
Utrecht, The Netherlands
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Regarding “Rib-cross thoracotomy for replacement of
the thoracoabdominal or total descending aorta”
In a recent issue of this journal, Dr Okita and colleagues
reported their experience with four patients in whom rib-cross
thoracotomy was performed for repair of thoracoabdominal or
entire descending aortic aneurysm (J Vasc Surg 2003;37:219-21).
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